PMCPA Case
| Case number | AUTH/2541/11/12 |
| Complainant | General practitioner (GP) |
| Company | Napp Pharmaceuticals Limited |
| Product | Flutiform (fluticasone/formoterol) |
| Channel | Email promotion to NHS email address (sent via third-party agency) |
| Issue | Alleged inappropriate promotional email/spam to NHS email; questioned compliance with email permission requirements |
| Applicable Code year | 2012 |
| Clauses considered | Clauses 9.1 and 9.9 |
| Panel decision | No breach |
| Key rationale | Evidence the complainant had agreed to receive promotional emails; unsubscribe information provided; company responsible for third-party activity but consent was demonstrated |
| Complaint received | 23 November 2012 |
| Case completed | 20 March 2013 |
| Appeal | No appeal |
| Material reference | UK/FLUT-12106 (certified October 2012) |
Download the full case report (PDF)
Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory
Got a question about this case?
Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.
⭐ Business Intelligence Access
See the full compliance picture for every pharma company
291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.
One real case. One key lesson. Every week — free.